JPWO2019197903A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019197903A5
JPWO2019197903A5 JP2021504589A JP2021504589A JPWO2019197903A5 JP WO2019197903 A5 JPWO2019197903 A5 JP WO2019197903A5 JP 2021504589 A JP2021504589 A JP 2021504589A JP 2021504589 A JP2021504589 A JP 2021504589A JP WO2019197903 A5 JPWO2019197903 A5 JP WO2019197903A5
Authority
JP
Japan
Prior art keywords
pdl
cancer
pharmaceutical composition
item
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021504589A
Other languages
English (en)
Japanese (ja)
Other versions
JP7423598B2 (ja
JP2021521274A5 (https=
JP2021521274A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000423 external-priority patent/WO2019197903A1/en
Publication of JP2021521274A publication Critical patent/JP2021521274A/ja
Publication of JPWO2019197903A5 publication Critical patent/JPWO2019197903A5/ja
Publication of JP2021521274A5 publication Critical patent/JP2021521274A5/ja
Priority to JP2024005463A priority Critical patent/JP2024054138A/ja
Application granted granted Critical
Publication of JP7423598B2 publication Critical patent/JP7423598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021504589A 2018-04-12 2019-04-11 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ Active JP7423598B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024005463A JP2024054138A (ja) 2018-04-12 2024-01-17 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18382248.5 2018-04-12
EP18382248 2018-04-12
EP18382326 2018-05-14
EP18382326.9 2018-05-14
EP18382360 2018-05-25
EP18382360.8 2018-05-25
EP19382132.9 2019-02-22
EP19382132 2019-02-22
PCT/IB2019/000423 WO2019197903A1 (en) 2018-04-12 2019-04-11 Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024005463A Division JP2024054138A (ja) 2018-04-12 2024-01-17 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ

Publications (4)

Publication Number Publication Date
JP2021521274A JP2021521274A (ja) 2021-08-26
JPWO2019197903A5 true JPWO2019197903A5 (https=) 2022-04-18
JP2021521274A5 JP2021521274A5 (https=) 2022-04-18
JP7423598B2 JP7423598B2 (ja) 2024-01-29

Family

ID=67060425

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504589A Active JP7423598B2 (ja) 2018-04-12 2019-04-11 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
JP2024005463A Ceased JP2024054138A (ja) 2018-04-12 2024-01-17 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024005463A Ceased JP2024054138A (ja) 2018-04-12 2024-01-17 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ

Country Status (11)

Country Link
US (1) US20210130453A1 (https=)
EP (1) EP3774895A1 (https=)
JP (2) JP7423598B2 (https=)
KR (1) KR20210021287A (https=)
CN (1) CN112585164A (https=)
AU (1) AU2019251289B2 (https=)
CA (1) CA3096779A1 (https=)
IL (1) IL277918A (https=)
MA (1) MA52231A (https=)
SG (1) SG11202009966SA (https=)
WO (1) WO2019197903A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof
AU2019269131B2 (en) * 2018-05-14 2024-02-22 Fundació Privada Institució Catalana De Recerca I Estudis Avançats Antibodies against LIF and dosage forms thereof
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
WO2021183370A1 (en) * 2020-03-11 2021-09-16 Purdue Research Foundation Compounds with immunomodulatory activity and therapeutic uses thereof
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof

Similar Documents

Publication Publication Date Title
JP2021521274A5 (https=)
CN105073133B (zh) 抗gdf15抗体
RU2698697C2 (ru) Конъюгаты связующего (ADC) с ингибиторами KSP
JP7244570B2 (ja) 小分子インテグリン受容体－リガンドアゴニストアジュバントを含む免疫治療のための新規組成物及び方法
JP2025013486A (ja) 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法
RU2017107559A (ru) Лечение раковых заболеваний с применением анти-nkg2a средств
KR20170016479A (ko) 아우리스타틴 유도체 및 그의 접합체
US11572408B2 (en) Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
KR20090046973A (ko) 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물
JP2020521478A5 (https=)
RU2740261C2 (ru) Комбинированное лекарственное средство
RU2007135167A (ru) Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
JP2025530213A (ja) Ｎｍｔ阻害剤を含む抗体薬物コンジュゲート及びその使用
CN116322691A (zh) T细胞双特异性抗体相关不良反应的预防或减轻
JPWO2019197903A5 (https=)
JP2020537690A (ja) プレクチン１結合抗体およびその使用
JP2024521418A (ja) 放射性免疫複合体とチェックポイント阻害剤併用療法
JP7451506B2 (ja) がんの治療用の薬学的組合せ
US11311619B2 (en) Integrin activator vaccine compositions
JPWO2020150639A5 (https=)
CA2577667A1 (en) 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase ie
JPWO2021091359A5 (https=)
EP3288585A2 (en) Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
HK1240076A1 (en) Combination drug
NZ625745B2 (en) FGFR antibody drug conjugates (ADCs) and the use thereof